A61K 31/553
Having at least one nitrogen and one oxygen as ring hetero atoms
Official title: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K31/553 (Having at least one nitrogen and one oxygen as ring hetero atoms) appears on 820 US grants and 1,758 published applications in this corpus.
Search patents in A61K- Granted patents
- 820
- Published applications
- 1,758
- Assignees
- 714
- Inventors
- 4,882
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 6 | 0 |
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 1 |
| 2002 | 10 | 18 |
| 2003 | 14 | 17 |
| 2004 | 8 | 33 |
| 2005 | 8 | 25 |
| 2006 | 12 | 46 |
| 2007 | 4 | 29 |
| 2008 | 10 | 34 |
| 2009 | 7 | 34 |
| 2010 | 11 | 38 |
| 2011 | 16 | 45 |
| 2012 | 18 | 43 |
| 2013 | 29 | 58 |
| 2014 | 28 | 88 |
| 2015 | 47 | 75 |
| 2016 | 75 | 88 |
| 2017 | 65 | 97 |
| 2018 | 68 | 78 |
| 2019 | 72 | 84 |
| 2020 | 44 | 79 |
| 2021 | 49 | 81 |
| 2022 | 33 | 80 |
| 2023 | 42 | 87 |
| 2024 | 46 | 167 |
| 2025 | 49 | 177 |
| 2026 | 33 | 156 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Inhibitors and uses thereof22 Sep 2026US 12,740,991 B2Vividion Therapeutics, Inc.
- Lactone and lactam containing compounds useful as immunomodulators1 Sep 2026US 12,723,041 B2Bristol-Myers Squibb Company
- KRas inhibitors1 Sep 2026US 12,723,053 B2Eli Lilly and Company
- Compounds for inhibition of inflammation25 Aug 2026US 12,714,716 B2Children's Medical Center Corporation
- Bicyclic compound and use thereof25 Aug 2026US 12,715,866 B2SK Biopharmaceuticals Co., Ltd.
- Modified liposome for drug delivery, use of liposome for drug delivery, especially with anti-cancer activity, and ways to load liposome with drugs, especially with anti-cancer activity8 Oct 2026US 2026/0306403 A1Bs Biotechna Spolka Akcyjna
- Stable polymer-lipid nanoparticle for drug binding and delivery, especially with anticancer properties, and a method for producing stable polymer-lipid nanoparticles carrying drugs, especially with anticancer properties8 Oct 2026US 2026/0306420 A1Bs Biotechna Spolka Akcyjna
- Pyrido[4,3-d]pyrimidine compounds8 Oct 2026US 2026/0306506 A1Pfizer Inc.
- Substituted oxoisoindolinyl piperidine-2,6-dione compounds and aza analogs thereof8 Oct 2026US 2026/0308147 A1
- Pharmaceutical composition comprising kras g12d inhibitor1 Oct 2026US 2026/0294931 A1Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Most cited
By later US patents
- Nanosuspensions for intravenous administration106US 5,726,164 ANovartis AG · 1998
- Small molecule toll-like receptor (TLR) antagonists91US 7,410,975 B2Coley Pharmaceutical GmbH · 2008
- Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof91US 8,129,519 B22012
- Prodrug comprising a drug linker conjugate85US 8,906,847 B2Ascendis Pharma A/S · 2014
- Aryl- or heteroaryl-substituted benzene compounds82US 8,410,088 B2Eisai R&D Management Co., Ltd. · 2013